At a glance
ClinicalIndex Comparison RecordN/ACompleted· 56 enrolled
Drug / intervention
ropivacaine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RePPAIR -Reducing Procedural Pain and Improving Recovery of Quality of Life in Pediatric Neuroblastoma Patients Undergoing Bone Marrow Procedures: A Prospective Randomized Cross-over Clinical Trial
In Brief
A clinical study evaluating propofol, ropivacaine, and 2 other interventions for Neuroblastoma. Completed, enrolled 56 participants across 1 site.
Detailed Summary
The purpose of this study is to identify whether or not the addition of a numbing medicine that is injected directly into the site of the bone marrow procedure can reduce pain and the use of opioid pain medication after bone marrow procedures. The addition of this medicine, called ropivacaine, is the experimental part of this study. This is the first time ropivacaine will be directly injected into the bone marrow site at MSKCC Pediatrics.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroblastoma
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedOct 2016
Primary CompletionNov 2019
TodayJul 2026
First PostedOct 5, 2016
Enrollment StartOct 1, 2016
Primary CompletionNov 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 9.7 years ago
Interventions
propofoldevice
ropivacainedrug
Wong-Baker FACES® Pain Rating Scalebehavioral
Nurses will record patient-reported pain scores.
Post-procedural quality of life (QOL)behavioral